FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Coliseum Capital Management, LLC 		2. Issuer Name and Ticker or Trading Symbol

BioScrip, Inc. [ BIOS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

METRO CENTER, 1 STATION PLACE, 7TH FLOOR SOUTH 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/20/2015
(Street)

STAMFORD, CT 06902
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock     (1) 5/20/2015     A      10000   (1)        (2)   (2) Common Stock   10000   (1) $0.00   (1) 10000   I   See Footnotes   (3) (4)

Explanation of Responses:
( 1)  Each share of phantom stock is a market-based cash award which is the economic equivalent of one share of the Issuer's common stock, par value $0.0001 per share (the "Common Stock"). Each share of phantom stock is entitled to a cash payment equal to the fair market value of a share of Common Stock as of the vesting date, based on the closing market price of the Common Stock on such date.
( 2)  The shares of phantom stock vest on the business day immediately preceding the date of the Issuer's 2016 annual meeting of stockholders, provided that Christopher Shackelton ("Shackelton") continues to serve as a director of the Issuer as of such date. If unvested on the vesting date, the shares of phantom stock expire.
( 3)  The phantom stock was received by Shackelton in connection with his service as a member of the board of directors of the Issuer. Shackelton has agreed that all equity awards he receives for serving as a director of the Issuer shall be issued to Coliseum Capital Partners, L.P. ("CCP").
( 4)  Shackelton and Adam Gray ("Gray") are managers of and have an ownership interest in each of (a) Coliseum Capital Management, LLC ("CCM"), the investment advisor to and a separate investment advisory account managed by CCM (the "Separate Account") and (b) Coliseum Capital, LLC ("CC"), the general partner of each of CCP and Coliseum Capital Partners II, L.P. ("CCP2") and may be deemed to have an indirect pecuniary interest in the shares held by CCP, CCP2, and the Separate Account due to CCM's right to receive performance-related fees from the Separate Account and CC's right to receive performance-related fees from CCP and CCP2. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of that person's pecuniary interest therein.

Remarks:
Shackelton is a director of the Issuer. As a result, the following persons may be deemed directors by deputization of the Issuer solely for purposes of Section 16 of the Securities Exchange Act of 1934, as amended: Gray, CCM, CC, CCP, and CCP2.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Coliseum Capital Management, LLC
METRO CENTER
1 STATION PLACE, 7TH FLOOR SOUTH
STAMFORD, CT 06902 		X X

Shackelton Christopher S
METRO CENTER
1 STATION PLACE, 7TH FLOOR SOUTH
STAMFORD, CT 06902 		X X

Coliseum Capital, LLC
METRO CENTER
1 STATION PLACE, 7TH FLOOR SOUTH
STAMFORD, CT 06902 		X X

COLISEUM CAPITAL PARTNERS L P
METRO CENTER
1 STATION PLACE, 7TH FLOOR SOUTH
STAMFORD, CT 06902 		X X

Coliseum Capital Partners II, L.P.
METRO CENTER
1 STATION PLACE, 7TH FLOOR SOUTH
STAMFORD, CT 06902 		X X

Gray Adam
METRO CENTER
1 STATION PLACE, 7TH FLOOR SOUTH
STAMFORD, CT 06902 		X X


Signatures
Coliseum Capital Management, LLC, By: /s/ Christopher Shackelton, Manager 5/22/2015
** Signature of Reporting Person Date

/s/ Christopher Shackelton 5/22/2015
** Signature of Reporting Person Date

Coliseum Capital, LLC, By: /s/ Christopher Shackelton, Manager 5/22/2015
** Signature of Reporting Person Date

Coliseum Capital Partners, L.P., By: Coliseum Capital, LLC, its General Partner, By: /s/ Christopher Shackelton, Manager 5/22/2015
** Signature of Reporting Person Date

Coliseum Capital Partners II, L.P., By: Coliseum Capital, LLC, its General Partner, By: /s/ Christopher Shackelton, Manager 5/22/2015
** Signature of Reporting Person Date

/s/ Adam Gray 5/22/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more BioPlus Acquisition Charts.
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more BioPlus Acquisition Charts.